SERA
Sera Prognostics, Inc.
Set alert
2.04 USD 0.00 -0.24%
2.03 Day range 2.09
1.59 52-week range 3.69
- YTD
- -30.85%
- 1 year
- -39.10%
- Open
- 2.09
- Prev close
- 2.05
- Mkt cap
- 80.48M
- Vol
- 85.99K
- Avg vol
- 22.12K
- EPS
- -0.67
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.03
- High
- 2.09
- Forward P/E
- -16.23
- Beta
- 1.04
- Short ratio
- 11.21
- Inst. own
- 71.54%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 7.31
- 200-d avg
- 7.94
- 1y target
- 0.00
Key statistics
- Market cap
- 290.44M
- Enterprise value
- 247.87M
- Trailing P/E
- 0.00
- Forward P/E
- -16.23
- PEG ratio
- 0.00
- Price / sales
- 3089.82
- Price / book
- 5.31
- EPS (TTM)
- -0.99
- Beta
- 1.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 94.00K
- Revenue growth
- -31.00%
- Free cash flow
- -5.26M
- Total cash
- 49.75M
- Total debt
- 1.10M
- Return on equity
- -49.58%
- Shares outstanding
- 32.80M
- Short % of float
- 3.13%
- 50-day average
- 7.31
- 200-day average
- 7.94
Analyst view
Consensus: none
Price target (mean) 0.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.24.
Financials — quick view
SERA Revenue — quarterly 30.00K
SERA Net income — quarterly -9.14M
SERA EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.22 | -0.24 | -0.02 | -9.09% |
| Aug 7, 2024 | Jun 1, 2024 | -0.23 | — | — | — |
| Aug 7, 2024 | Jun 1, 2024 | -0.23 | -0.25 | -0.02 | -8.70% |
| May 8, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.23 | -0.25 | -0.02 | -8.70% |
| Mar 20, 2024 | Dec 1, 2023 | -0.25 | -0.25 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 2023 | Citigroup | main | Neutral | Neutral |
| Nov 10, 2022 | Citigroup | main | — | Neutral |
| Aug 29, 2022 | Oppenheimer | main | — | Outperform |
| Apr 27, 2022 | Berenberg | init | — | Buy |
| Mar 30, 2022 | Citigroup | down | Buy | Neutral |
| Nov 19, 2021 | Oppenheimer | init | — | Outperform |
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- seraprognostics.com
News
- SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
- SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
- Sera Prognostics Q2 Earnings Call Highlights
- Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript
- Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates
- Sera Prognostics Q2 EPS $(0.18) Misses $(0.15) Estimate, Sales $30.000K Miss $57.500K Estimate
- SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
- SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
Your note
Sign in to keep a note on SERA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AERTS AUSTIN | Chief Financial Officer | Sale | Dec 9, 2024 | 285,756 |
| BONIFACE JOHN J | Officer | Sale | Nov 10, 2024 | 125,120 |
| CRITCHFIELD GREGORY C | Director | Stock Award(Grant) | Jun 5, 2024 | 807,270 |
| HARRISON ROBERT GARDNER | Chief Technology Officer | Sale | Nov 10, 2024 | 131,046 |
| JACKSON BENJAMIN R | General Counsel | Sale | Nov 10, 2024 | 135,528 |
| KEARNEY PAUL | Officer | Sale | Nov 10, 2024 | 176,889 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 16.57% | 5,434,399 | 46.74M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.25% | 3,032,808 | 26.08M | Sep 29, 2024 |
| Vivo Capital, LLC | 5.03% | 1,650,440 | 14.19M | Sep 29, 2024 |
| Blackrock Inc. | 4.70% | 1,540,281 | 13.25M | Sep 29, 2024 |
| Vanguard Group Inc | 3.66% | 1,199,509 | 10.32M | Sep 29, 2024 |
| JP Morgan Chase & Company | 2.70% | 884,867 | 7.61M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 2.13% | 697,621 | 6.00M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.09% | 684,412 | 5.89M | Sep 29, 2024 |
| Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 1.76% | 578,726 | 4.98M | Sep 29, 2024 |
| JP Morgan U.S. Small Company Fund | 1.04% | 341,523 | 2.94M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.86% | 283,082 | 2.43M | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.85% | 279,223 | 2.40M | Sep 29, 2024 |